The Facioscapulohumeral Muscular Dystrophy (FSHD) market is witnessing notable evolution as research sheds light on its underlying mechanisms and potential therapeutic targets. Advancements in gene therapy and molecular diagnostics are driving the development of innovative treatments, offering hope to patients and clinicians alike. Additionally, collaborative efforts among pharmaceutical companies, research institutions, and patient advocacy groups are accelerating the pace of progress, promising a brighter outlook for those affected by FSHD.
DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2034″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Facioscapulohumeral Muscular Dystrophy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Facioscapulohumeral Muscular Dystrophy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Facioscapulohumeral Muscular Dystrophy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Facioscapulohumeral Muscular Dystrophy: An Overview
Facioscapulohumeral Muscular Dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a disorder characterized by muscle weakness and wasting (atrophy). The disorder gets its name from muscles that are affected in the face (facio), around the shoulder blades (scapulo), and in the upper arms (humeral). Hamstring and trunk muscles are affected -early on but are less well recognized. Other arm and leg muscles are frequently eventually affected in the course of the disease.
FSHD is a genetically acquired disease that leads to progressive muscle weakness and severely decreased functional capacity in affected individuals-understanding how epigenetic factors interplay has evolved substantially in recent years.
FSHD can mimic many other genetic myopathies: particularly limb-girdle muscular dystrophy, subacute necrotizing encephalomyelopathy, acid maltase deficiency, myotonic dystrophy, and polymyositis. In cases of significant symptom overlap between myopathies, genetic testing remains the standard in distinguishing between disease pathology.
Facioscapulohumeral Muscular Dystrophy Market Key Facts
• In 2021, the total Facioscapulohumeral Muscular Dystrophy market size was USD 25.55 million.
• The total Facioscapulohumeral Muscular Dystrophy market size in the United States accounted for USD 19.83 million in 2021.
• In EU4 (Germany, France, Italy, and Spain) and the United Kingdom, the total Facioscapulohumeral Muscular Dystrophy market size was USD 3.34 million in 2021.
• In the year 2021, the total prevalent cases of FSHD were 78,790 in the 7MM.
• In the 7MM, the highest number of total prevalent cases of FSHD were observed in the United States, with 33,500 cases in 2021, estimated to increase by 2032 at a moderate CAGR.
• The total prevalent cases of FSHD in EU4 and the UK comprised 32,821 cases in 2021 and are projected to increase by 2032, at a moderate CAGR during the forecast period (2021-2032).
• Among the EU4 and the UK, the highest number of total prevalent cases of FSHD was observed in Germany, with 8,441 cases in 2021, estimated to decrease by 2032 at a moderate CAGR.
• The total prevalent cases of FSHD in Japan comprised 12,469 cases in 2021 and are projected to decrease by 2032, at a moderate CAGR during the forecast period (2021-2032).
Get a Detailed Overview of the Evolving Facioscapulohumeral Muscular Dystrophy Market Trends @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Facioscapulohumeral Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Facioscapulohumeral Muscular Dystrophy therapies in the market. It also provides a detailed assessment of the Facioscapulohumeral Muscular Dystrophy market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete details of the market trend for each marketed Facioscapulohumeral Muscular Dystrophy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Discover How the Facioscapulohumeral Muscular Dystrophy Market Will Grow by 2034@
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Facioscapulohumeral Muscular Dystrophy Epidemiology
The epidemiology section covers detailed insights into the historical, and current Facioscapulohumeral Muscular Dystrophy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Facioscapulohumeral Muscular Dystrophy Epidemiology Segmented as –
• Total Prevalent Cases of Facioscapulohumeral Muscular Dystrophy
• Total Diagnosed Cases of Facioscapulohumeral Muscular Dystrophy
• Total Type-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Gender-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Age-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Severity-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Treated Cases of Facioscapulohumeral Muscular Dystrophy
Get Key Insights Into the Evolving Facioscapulohumeral Muscular Dystrophy Epidemiology Trends @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the market share by Facioscapulohumeral Muscular Dystrophy drugs, patient uptake by therapies, and sales of each drug.
The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Facioscapulohumeral Muscular Dystrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities in the Facioscapulohumeral Muscular Dystrophy Market @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Facioscapulohumeral Muscular Dystrophy Therapeutics Assessment
There are currently no disease-modifying treatments for Facioscapulohumeral Muscular Dystrophy (FSHD); supportive care is the mainstay of managing FSHD. This care primarily occurs in the context of physical therapy and rehabilitation exercises. Managing pain and fatigue in FSHD patients is essential, as both symptoms can affect patient psychology. Chronic pain is manageable with analgesic and antidepressant therapy to improve the quality of life in FSHD patients. To improve the treatment scenario, globally, several key companies are actively working in the Facioscapulohumeral Muscular Dystrophy therapeutics market landscape.
On March 07, 2024, Solid Biosciences Inc. (Nasdaq: SLDB) announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD). The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.
Leading Companies in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market Include
• Fulcrum Therapeutics
• Dyne Therapeutics.
• Hoffmann-La Roche
• aTyr Pharma, Inc.
• Avidity Biosciences, Inc.
And Many Others
Emerging and Marketed Facioscapulohumeral Muscular Dystrophy Therapies Covered in the Report Include:
• Losmapimod: Fulcrum Therapeutics
• DYNE-301: Dyne Therapeutics
And Many More
Learn More About the Emerging Therapies and key Companies in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Competitive Intelligence Analysis
4. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance
5. Facioscapulohumeral Muscular Dystrophy Background and Overview
6. Facioscapulohumeral Muscular Dystrophy Patient Journey
7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population
8. Facioscapulohumeral Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Facioscapulohumeral Muscular Dystrophy Unmet Needs
10. Key Endpoints of Facioscapulohumeral Muscular Dystrophy Treatment
11. Facioscapulohumeral Muscular Dystrophy Marketed Products
12. Facioscapulohumeral Muscular Dystrophy Emerging Therapies
13. Facioscapulohumeral Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Facioscapulohumeral Muscular Dystrophy Market Outlook (7 major markets)
16. Facioscapulohumeral Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Facioscapulohumeral Muscular Dystrophy Market.
18. Facioscapulohumeral Muscular Dystrophy Market Drivers
19. Facioscapulohumeral Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report’s Offerings @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=libero&utm_medium=pressrelease&utm_campaign=rkpr
Contact Info:
Ram Kapoor
Executive (Marketing & Branding)
Email: info@delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.